Last reviewed · How we verify
FluLavalTM-YB
FluLaval-YB is a quadrivalent inactivated influenza vaccine that stimulates immune response against four strains of influenza virus.
FluLaval-YB is a quadrivalent inactivated influenza vaccine that stimulates immune response against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | FluLavalTM-YB |
|---|---|
| Also known as | FluLavalTM containing the Yamagata B flu strain, FluLaval®-YB |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens representing two influenza A strains and two influenza B strains. Upon administration, it triggers both humoral (antibody) and cellular immune responses, enabling the body to recognize and neutralize circulating influenza viruses before infection occurs. This provides seasonal protection against the included viral strains.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluLavalTM-YB CI brief — competitive landscape report
- FluLavalTM-YB updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI